M.D., executive vice president of Research and Development at Amgen. 2 "LUMAKRAS plus Vectibix offers a targeted, biomarker-driven combination therapy that helps delay disease progression more ...

Amgen AMGN announced that the FDA has approved its KRAS inhibitor, Lumakras (sotorasib), in combination with its anti-EGFR ...

Amgen announced that the US Food and Drug Administration (FDA) has approved Lumakras (sotorasib) in combination with Vectibix (panitumumab) for the treatment of adult patients with KRAS G12C-mutated ...

According to a statement from the agency on Thursday, Lumakras, also known as sotorasib, will be indicated in the U.S. with Amgen’s (NASDAQ:AMGN) epidermal growth factor receptor (EGFR ...

OS of sotorasib-panitumumab versus investigator's choice ... part of Cactus Communications); and Christopher Nosala, PhD, CMPP (Amgen Inc.) and was funded by Amgen Inc. Presented as a rapid oral at ...

Amgen and the Federal Trade Commission are settling the lawsuit the regulator filed to block the pharmaceutical giant’s $28 billion Horizon Therapeutics acquisition. As part of the settlement ...

The new study, conducted with support from Amgen Inc., builds on previous research by Dr. Fakih’s team that found sotorasib could be made more effective when combined with panitumumab. City of Hope is ...

approval for its LUMAKRAS (sotorasib) and Vectibix (panitumumab) combination therapy for treating adults with KRAS G12C-mutated metastatic colorectal cancer. "Amgen opens new drug substance ...

The new study, conducted with support from Amgen Inc., builds on previous research by Dr. Fakih’s team that found sotorasib could be made more effective when combined with panitumumab.